// App-Quantinova.ai

1002 : IDH1 promotes tumor growth and resistance to targeted therapies in the absence of mutation

Researchers

Presenter

  • Alexander H. Stegh

Principal Investigators

  • N/A

Medical Centers

  • Northwestern University Lurie Cancer Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Low-grade gliomas

  • Glioblastoma

  • Solid malignancies

  • Gliomas

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Isocitrate dehydrogenase 1

  • Isocitrate dehydrogenase 2

Drug/Treatment

  • glutathione

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved